A randomised, parallel group trial comparing two stepwise treatment tracks for the pharmacological management of adult asthma: ICS/formoterol reliever vs SABA reliever-based therapy

开始日期2025-04-11

申办/合作机构

Medical Research Institute of New Zealand

NCT06865040

/ Not yet recruitingN/AIIT

Perioperative Inhaled Therapy in Carcinological Thoracic Surgery in Patients At High Risk of Postoperative Pulmonary Complications

The objective of the study is to evaluate, in a clinical trial, the efficacy of peri operative administration of long-acting inhaled ß-2 mimetics on the occurrence of postoperative pulmonary complications

开始日期2025-03-04

申办/合作机构

Centre Hospitalier Universitaire Amiens-Picardie

CTRI/2024/10/075606

/ Recruiting临床3期

A randomized, double-blind, double-dummy clinical trial to assess the efficacy and safety of fixed dose combination of Glycopyrronium 25 µg, Formoterol Fumarate 20 µg, Budesonide 500 µg Inhalation Suspension (for nebulization) in comparison with fixed dose combination of Formoterol Fumarate Dihydrate 5 µg, Glycopyrronium 7.2 µg and Budesonide 160 µg pressured inhalation suspension in patients with chronic obstructive pulmonary disease. - NIL

开始日期2024-11-07

申办/合作机构

Glenmark Pharmaceuticals Ltd.

100 项与富马酸福莫特罗相关的临床结果

登录后查看更多信息

100 项与富马酸福莫特罗相关的转化医学

登录后查看更多信息

100 项与富马酸福莫特罗相关的专利（医药）

登录后查看更多信息

3,683

项与富马酸福莫特罗相关的文献（医药）

2025-12-31·Pulmonology

Adherence to inhaled corticosteroids and long-acting β2-agonists in asthma: A MASK-air study

Article

作者: Makela, M. ; Bedbrook, A. ; Samolinski, B. ; Klimek, L. ; Rivero Yeverino, D. ; Kuna, P. ; Canonica, G.W. ; Ollert, M. ; Agache, I. ; Usmani, O.S. ; Jutel, M. ; Gemicioglu, B. ; Shamji, M.H. ; Puggioni, F. ; Cecchi, L. ; Buhl, R. ; Ivancevich, J.C. ; Kraxner, H. ; Anto, J.M. ; Pétré, B. ; Haahtela, T. ; Nadif, R. ; Amaral, R. ; Boulet, L.-P. ; Papadopoulos, N.G. ; Robalo Cordeiro, C. ; Bonini, M. ; Zuberbier, T. ; Bousquet, J. ; Ventura, M.T. ; Morais-Almeida, M. ; Costa, E.M. ; Patella, V. ; Czarlewski, W. ; Fonseca, J.A. ; Roche, N. ; Brusselle, G. ; Sá-Sousa, A. ; Chaves Loureiro, C. ; Louis, R. ; Kupczyk, M. ; Bergmann, K.C. ; Becker, S. ; Sastre, J. ; Brussino, L. ; Sousa-Pinto, B. ; Romantowski, J. ; Regateiro, F.S. ; Laune, D. ; Sheikh, A. ; Niedoszytko, M. ; Valiulis, A. ; Yorgancioglu, A. ; Savouré, M. ; Scichilone, N. ; Charpin, D. ; Suppli Ulrik, C. ; Bosnic-Anticevich, S. ; Larenas-Linnemann, D.E. ; de Blay, F. ; Pfaar, O. ; Papi, A. ; Taborda-Barata, L. ; Cruz, A.A. ; Pham-Thi, N. ; Okamoto, Y. ; Kvedariene, V. ; Rouadi, P.W. ; Del Giacco, S.

INTRODUCTION:

Adherence to controller medication is a major problem in asthma management, being difficult to assess and tackle. mHealth apps can be used to assess adherence. We aimed to assess the adherence to inhaled corticosteroids+long-acting β2-agonists (ICS+LABA) in users of the MASK-air® app, comparing the adherence to ICS+formoterol (ICS+F) with that to ICS+other LABA.

MATERIALS AND METHODS:

We analysed complete weeks of MASK-air® data (2015-2022; 27 countries) from patients with self-reported asthma and ICS+LABA use. We compared patients reporting ICS+F versus ICS+other LABA on adherence levels, symptoms and symptom-medication scores. We built regression models to assess whether adherence to ICS+LABA was associated with asthma control or short-acting beta-agonist (SABA) use. Sensitivity analyses were performed considering the weeks with no more than one missing day.

RESULTS:

In 2598 ICS+LABA users, 621 (23.9%) reported 4824 complete weeks and 866 (33.3%) reported weeks with at most one missing day. Higher adherence (use of medication ≥80% of weekly days) was observed for ICS+other LABA (75.1%) when compared to ICS+F (59.3%), despite both groups displaying similar asthma control and work productivity. The ICS+other LABA group was associated with more days of SABA use than the ICS+F group (median=71.4% versus 57.1% days). Each additional weekly day of ICS+F use was associated with a 4.1% less risk in weekly SABA use (95%CI=-6.5;-1.6%;p=0.001). For ICS+other LABA, the percentage was 8.2 (95%CI=-11.6;-5.0%;p<0.001).

CONCLUSIONS:

In asthma patients adherent to the MASK-air app, adherence to ICS+LABA was high. ICS+F users reported lower adherence but also a lower SABA use and a similar level of control.

2025-12-31·Journal of Pharmaceutical Policy and Practice

Access to single-inhaler triple medicines for chronic obstructive pulmonary disease in China: a national survey on accessibility and utilisation

Article

作者: Wang, Menglei ; Yu, Shule ; Yang, Qingqing ; Lu, Wei ; Guo, Wei ; Zheng, Fangfang ; Wu, Huanhuan ; Chen, Hongdou ; Li, Wei

Background:

The maintenance medicines for chronic obstructive pulmonary disease (COPD) include inhaled corticosteroids (ICS), long-acting muscarinic antagonists (LAMA) and long-acting β2-agonists (LABA). Budesonide/glycopyrronium/formoterol (BUD/GLY/FOR) and fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) are two representative drugs for prefixed ICS/LAMA/LABA association in a single inhaler and have shown comparable efficacy and safety with other ICS/LAMA/LABA open combination therapies in patients with moderate-to-very severe COPD. This study aimed to investigate the availability, price, affordability, and utilisation of single-inhaler triple medicines for COPD in China.

Methods:

Quarterly data about the use of BUD/GLY/FOR and FF/UMEC/VI from 2020 to 2022 were collected from the Chinese Medicine Economic Information Network. We used the adjusted World Health Organization and Health Action International methodology to calculate the availability and affordability of the two investigated medicines in 596 tertiary general hospitals and 299 secondary general hospitals in 31 provincial administrative regions in China.

Results:

The availability and consumption of BUD/GLY/FOR were significantly higher than those of FF/UMEC/VI during the study period. At the end of 2022, the availability of BUD/GLY/FOR and FF/UMEC/VI in tertiary general hospitals was 69.80% and 52.01% respectively, while in secondary general hospitals, it was 52.51% and 28.76% respectively. Both medications were equally affordable at 1.3 days of the minimum wage after reimbursement in 2022. In the first quarter of 2021, with the inclusion of both drugs in the Medicare catalog, their DDDc decreased significantly, which was accompanied by notable improvements in their availability, affordability and consumption.

Conclusions:

The overall accessibility and consumption of BUD/GLY/FOR and FF/UMEC/VI were improved in China from 2020 to 2022. The implementation of the national drug price negotiation policy reduces the cost of drugs in China and plays an important role in improving the availability of the investigated drugs.

2025-07-01·PHYTOMEDICINE

Oligomeric proanthocyanidin attenuates asthma severity and airway remodeling by modulating epithelial-smooth muscle cell interactions

Article

作者: Zeng, Xiaoning ; Zhong, Xiuhua ; Gu, Shengwei ; Liang, Wenyan ; Ma, Yuan ; Yao, Xin ; Gu, Hao ; Gu, Yihang ; Liu, Yanan

BACKGROUND:

As a significant instigator of asthma pathogenesis, the airway epithelium produces cytokines that disrupt lung homeostasis and contribute to airway remodeling. Although efforts are directed in the management of this progress but few have proved effective. Recently, there is a cue that oligomeric proanthocyanidin (OPC), a widely used antioxidant supplement extracted from grape seeds with a broad safety margin, presents potential in asthmatic mice while the mechanism remains unclear.

PURPOSE:

To elucidate the impacts of OPC on asthma and the potential mechanisms that may be involved.

STUDY DESIGN:

Asthma patients, OVA-sensitized mice, human bronchial epithelial (BE) cells and airway smooth muscle (ASM) cells were included to explore the effect of OPC on asthma, with a particular focus on the underlying mechanism.

METHODS:

34 patients with asthma were enrolled in three treatment groups randomized to a standard budesonide/formoterol inhalation with or without the oral OPC supplementation for 8 weeks. BALB/c mice were sensitized and challenged with OVA to establish an asthmatic model, pretreated with or without OPC. BE cells were stimulated with TNF-α to mimic an inflammatory epithelial state in asthma, and ASM cells were incubated with the supernatant collected from BE cells to construct a conditioned co-culture system.

RESULTS:

Patients supplemented with OPC showed more improvements in asthma control test scores, forced expiratory volume in one second, and peripheral eosinophil counts. In OVA-sensitized mice, OPC administration exhibited superior benefits in airway hyperresponsiveness, inflammation and remodeling, additionally with a suppression in malondialdehyde levels. Further analysis using an inflammatory epithelial cell model demonstrated that OPC reduced the secretion of epithelial-derived cytokines, including eotaxin-1 and TGF-β1. This reduction is likely due to the decreased intracellular ROS signal, which were confirmed by using H₂O₂ and the ROS scavenger N-acetylcysteine. With the co-culture of epithelial and airway smooth muscle cells, OPC was indicated to inhibit ASM cell proliferation by reducing epithelial-derived TGF-β1, potentially through the p38 pathway.

CONCLUSION:

Our findings provide the first evidence that OPC may offer a promising approach to clinical asthma management by modulating communication between airway structural cells, highlighting the potential of OPC as a potent option to mitigate airway remodeling in asthma.

227

项与富马酸福莫特罗相关的新闻（医药）

2025-05-19

·药筛

药交会前瞻：最卷的100个药品

参加广州药交会，提前做好产品攻略！纯干货，无废话。这是系列四：2024年1月1日-2025年4月30日获批企业数量排名前100药品。排名药品名称持有人数量1地夸磷索钠滴眼液362间苯三酚注射液343乳果糖口服溶液304米诺地尔搽剂295二羟丙茶碱注射液276玻璃酸钠滴眼液267法莫替丁注射液268他达拉非片269硫酸氨基葡萄糖胶囊2510帕拉米韦注射液2311磷酸奥司他韦干混悬剂2212磷酸奥司他韦胶囊2213己酮可可碱注射液2114氨溴特罗口服溶液2015复方聚乙二醇电解质散(III)1916注射用尼可地尔1917达格列净片1718利丙双卡因乳膏1719罗沙司他胶囊1720吸入用乙酰半胱氨酸溶液1721恩格列净片1622盐酸乌拉地尔注射液1623阿戈美拉汀片1524富马酸福莫特罗吸入溶液1525硫酸镁钠钾口服用浓溶液1526注射用盐酸罗沙替丁醋酸酯1527磷酸西格列汀片1428马来酸阿伐曲泊帕片1429美索巴莫注射液1430盐酸多巴酚丁胺注射液1431吲哚布芬片1432注射用氯诺昔康1433甲钴胺片1334氯化钾颗粒1335氯化钾注射液1336马来酸氟伏沙明片1337普拉洛芬滴眼液1338沙库巴曲缬沙坦钠片1339腺苷钴胺胶囊1340盐酸奥洛他定滴眼液1341盐酸达泊西汀片1342注射用头孢唑肟钠1343二甲双胍恩格列净片(Ⅰ)1244富马酸伏诺拉生片1245盐酸艾司洛尔注射液1246盐酸多巴胺注射液1247盐酸莫西沙星滴眼液1248盐酸莫西沙星氯化钠注射液1249艾曲泊帕乙醇胺片1150普瑞巴林胶囊1151瑞巴派特片1152西格列汀二甲双胍片(Ⅱ)1153盐酸氨溴索口服溶液1154盐酸丙卡特罗口服溶液1155地氯雷他定口服溶液1056非布司他片1057硫酸镁注射液1058麦考酚钠肠溶片1059盐酸去氧肾上腺素注射液1060盐酸左沙丁胺醇雾化吸入溶液1061左氧氟沙星滴眼液1062阿加曲班注射液963枸橼酸西地那非口崩片964拉考沙胺注射液965莫匹罗星软膏966普瑞巴林口服溶液967氢溴酸伏硫西汀片968瑞戈非尼片969重酒石酸间羟胺注射液970重酒石酸去甲肾上腺素注射液971注射用头孢他啶阿维巴坦钠972左乙拉西坦口服溶液973阿司匹林肠溶片874布洛芬混悬液875地诺孕素片876多巴丝肼片877多索茶碱注射液878二甲双胍恩格列净片(Ⅵ)879甲硫酸新斯的明注射液880聚乙烯醇滴眼液881硫酸羟氯喹片882铝碳酸镁咀嚼片883米拉贝隆缓释片884舒更葡糖钠注射液885碳酸氢钠林格注射液886头孢地尼颗粒887吸入用硫酸沙丁胺醇溶液888硝酸异山梨酯注射液889熊去氧胆酸胶囊890溴芬酸钠滴眼液891依折麦布片892左卡尼汀口服溶液893艾司奥美拉唑镁肠溶胶囊794奥拉帕利片795奥美沙坦酯氨氯地平片796奥硝唑注射液797倍他米松磷酸钠注射液798吡拉西坦注射液799富马酸丙酚替诺福韦片7100钆特酸葡胺注射液7101枸橼酸托法替布片7102骨化三醇软胶囊7103甲磺酸雷沙吉兰片7104酒石酸溴莫尼定滴眼液7105聚乙二醇4000散7106利奈唑胺葡萄糖注射液7107硫酸沙丁胺醇注射液7108硫酸特布他林雾化吸入用溶液7109罗库溴铵注射液7110洛索洛芬钠凝胶贴膏7111氯化钾口服溶液7112他氟前列素滴眼液7113碳酸镧咀嚼片7114维格列汀片7115西甲硅油乳剂7116吸入用复方异丙托溴铵溶液7117吸入用盐酸丙卡特罗溶液7118缬沙坦氨氯地平片(Ⅰ)7119盐酸胺碘酮注射液7120盐酸氮卓斯汀滴眼液7121依帕司他片7122注射用厄他培南钠7123左卡尼汀注射液7124左西孟旦注射液7125左氧氟沙星氯化钠注射液7126左氧氟沙星片7（手工整理，如有错误或遗漏，欢迎补充）用摩熵药筛小程序，快速查询产品信息。

申请上市

2025-05-13

·Pharmaceutical Technology

MHRA approves AstraZeneca’s Trixeo Aerosphere inhaler for COPD

AstraZeneca plans to transition its pMDI portfolio to the near-zero GWP propellant by 2030. Credit: Elzbieta Krzysztof / Shutterstock. The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved AstraZeneca’s Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF) inhaler for use with a propellant with near-zero Global Warming Potential (GWP), to treat adults with chronic obstructive pulmonary disease (COPD). This step marks the first time a medicine delivered by a pressurised metered-dose inhaler (pMDI) utilises a propellant with a 99.9% lower GWP compared to currently used propellants. The approval was based on the propellant clinical development programme outcomes, which confirmed bioequivalence between Trixeo with the new propellant, HFO-1234ze(E), and the existing propellant, HFA-134a. Trixeo’s tolerability and safety profile were found to be consistent with its known characteristics. Trixeo, known as Breztri Aerosphere in the US, China, and Japan, is a fixed-dose triple-combination therapy for COPD. The therapy combines a long-acting β2 agonist (LABA), a long-acting muscarinic antagonist (LAMA), and an inhaled corticosteroid (ICS), delivered through the Aerosphere pMDI. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence AstraZeneca plans to transition its pMDI portfolio to the near-zero GWP propellant by 2030, aligning with its Ambition Zero Carbon strategy. The transition of Trixeo Aerosphere in the UK is set to begin in the coming months. Regulatory applications for Trixeo/Breztri Aerosphere with the next-generation propellant are also under review in China, Europe, and other nations. AstraZeneca biopharmaceuticals business unit executive vice-president Ruud Dobber said: “The UK approval of Trixeo Aerosphere with the next-generation propellant is an industry first and a major milestone in AstraZeneca’s commitment to transition our pMDI portfolio to the propellant with near-zero GWP. “Starting with Trixeo, we are addressing the needs of both patients and the environment in devastating diseases like COPD, which affects hundreds of millions of people and is a leading cause of death globally.” Honeywell-developed medical-grade HFO-1234ze(E) is pivotal for decreasing the climate impact of pMDI medicines. In 2022, AstraZeneca announced a partnership with Honeywell to develop respiratory inhaled medicines with the new propellant. As part of its Ambition Zero Carbon strategy, AstraZeneca is progressing towards net zero emissions, targeting a 98% reduction in greenhouse gas emissions from its operations by 2026, from a 2015 baseline.

上市批准

2025-05-12

·BFC医疗投资资讯

BFC医疗健康行业资本市场周报(5/12)

BFC Group简介BFC Group是一家立足于中国的精品投行，专注于医疗健康领域的并购、专利许可、融资。我们的业务板块涉及中国、美国和欧洲，曾与国内外众多领先的医疗健康公司有过合作并保持着良好的关系。随着在美国和中国一线运营经验的不断积累，我们对客户在本土之外建立公司或扩展业务所面临的挑战有着深刻的理解。立于塔顶，高瞻之见。使命愿景紧跟医疗健康领域趋势，通过合作推动科学突破与创新。依客户需求制定战略拓展计划，并在目标市场全方位落实与执行。成为专注医疗健康行业最优秀的投资银行。No.1香港资本市场香港股市总体概览上周港股延续升势，恒生指数累计上涨1.6%。随着中美高层即将在瑞士会面，市场对关税问题的担忧有所缓解。此外，美国财政部表示关税战“将在短时间内缓和”，释放出降温信号，提升了市场情绪。5月7日，中国政府发布了一揽子金融政策，旨在“稳市场、稳预期、扩内需、促科创、扶企业”，进一步为港股市场提供有力支撑。2025年至今，恒生指数累计上涨14.0%。上周，恒生医疗保健指数(HSHCI)累计下跌3.7%。远大医药上周股价累计上涨25.97%，受多项利好消息推动。5月6日，集团宣布全球创新药物STC3141在中国开展的用于治疗脓毒症的II期临床研究成功达到临床终点。STC3141为远大医药自主开发的、拥有全球知识产权的、具有全新作用机制的小分子化合物，通过中和胞外游离组蛋白和中性粒细胞诱捕网来逆转机体过度免疫反应造成的器官损伤，可用于多种重症适应症。5月7日，集团宣布加入国际多中心 III 期临床试验的申请近日已获得中华人民共和国国家药品监督管理局正式受理。TLX591 (177Lu-rosopatamab tetraxetan)是一款基于放射性核素-抗体偶联技术的PSMA靶向治疗性放射性药物。本次III期试验拟在中国、美国、澳大利亚、新西兰等全球多个国家入组500余名患者，旨在评估TLX591联合标准治疗与仅接受标准治疗相比，在既往接受过雄激素受体通路抑制剂(ARPI)治疗进展的转移性去势抵抗性前列腺癌患者(mCRPC)中的疗效和安全性。2025年至今，医药板块领先大盘，恒生医疗保健指数累计上涨24.3%，高于恒生指数10.3个百分点。香港股市医疗健康板块概览2025年4月恒生医疗保健指数上涨1.1%。上周市值前20个股涨跌互现，部分个股显著下跌。5月1日，翰森制药宣布，公司自主研发的B4-H4靶向抗体-药物偶联物（ADC）注射用HS-20089获国家药品监督管理局（NMPA）批准纳入“突破性治疗药物”，拟定适应症为用于治疗铂耐药复发上皮性卵巢癌、输卵管癌或原发性腹膜癌患者。HS-20089是一款B7-H4靶向ADC，其有效载荷为拓扑异构酶抑制剂（TOPOi），正于中国开展用于治疗卵巢癌以及其他妇科肿瘤的多项临床研究，其中最高研究阶段为临床Ⅲ期。香港股市医疗健康板块证券发行2024年共计有12家企业上市(其中3家为依照18A新规上市的未盈利生物医药公司)，共募集金额54.0亿港元。2025年截至目前，共有3家企业上市(其中2家为依照18A新规上市的未盈利生物医药公司)，数量与去年同期持平，金额总数上领先去年同期131.4%。上周无新增IPO。2024年共计19家企业完成定增，共募资金额80.9亿港元。2025年至今，共有9家企业完成定增，数量领先去年同期28.6%，金额总数上领先去年同期143.6%。5月6日，一脉阳光宣布按配售价每股配售股份20.00港元向不少于六名承配人成功配售975万股配售股份，共募集资金1.95亿港元，所募资金将用于影像中心业务投资及并购、海外业务拓展、医学影像AI研发以及营运。香港股市医疗健康板块IPO动态港股医疗板块拟上市企业No.2沪深资本市场沪深股市总体股市概览上周，上证指数上涨1.9%，沪深300上涨2.0%。第八届数字中国建设峰会闭幕。本届峰会共吸引超36万人次参会观展，创历史新高，峰会成果丰硕。在产业对接方面，本届峰会共签约数字经济重点项目455个、总投资额2280亿元，比上届峰会分别增长8%和12%，项目涵盖新一代人工智能、机器人、算力基础设施、互联网医疗等多个领域。截至目前，2025年上证综指下跌0.3%，沪深300下跌2.3%。上周，上证医药上涨0.5%，医药中信指数上涨1.0%。近日，工业和信息化部、商务部、国家卫生健康委、国家医保局、国家数据局、国家中医药局、国家药监局等七部门联合发布实施《医药工业数智化转型实施方案（2025—2030年）》（以下简称《实施方案》）。《实施方案》提出，到2030年，规上医药工业企业基本实现数智化转型全覆盖，数智技术融合创新能力大幅提升，医药工业全链条数据体系进一步完善，医药工业数智化转型生态体系进一步健全。2025年，A股医药板块回暖。上证医药上涨4.7%，领先上证综指5个百分点。医药中信指数上涨1.3%，领先沪深300指数3.6个百分点。沪深股市医疗健康板块概览2024年医药中信指数下跌6.77%。继2025年3月回升1.3%后，4月再度转弱，下降1.9%。上周市值前20个股涨跌互现。今年以来，复星医药多项创新成果持续兑现，近日发布2025Q1财报显示，一季度实现营业收入94.20亿元，同比下滑7.26%；归母净利润7.65亿元，同比增长25.42%；经营活动现金流10.56亿元。营收下滑主要是受药品集采续标及部分地方药品集采开展的影响。报告期内，复星医药持续推进非战略非核心资产的退出和整合，持续推进资产结构优化，加速现金回流。5月7日，百济神州发布2025年一季报，在美国通用会计准则（GAAP）下首次实现了季度盈利。期内营收80.48亿元，同比增长50.2%，其中产品收入79.85亿元，同比增长49.9%。百济神州的业绩增长主要得益于其核心自研产品BTK抑制剂百悦泽（泽布替尼）和PD-1抗癌药百泽安（替雷利珠单抗），以及安进授权产品的销售增长。今年第一季度，泽布替尼全球销售额为56.92亿元，同比增长63.7%。百济神州称，泽布替尼本季度首次位居美国BTK抑制剂领域市场份额首位。沪深股市医疗健康板块概览上周，创新药指数上涨1.4%，医疗器械指数上涨1.5%。恒瑞医药羟乙磺酸达尔西利片上市许可申请获受理：5月8日，恒瑞医药公告称，公司自主研发的CDK4/6（细胞周期蛋白依赖性激酶4/6）抑制剂羟乙磺酸达尔西利片药品上市许可申请获国家药监局受理。该药品拟定适应症为联合内分泌治疗用于激素受体（HR）阳性，人表皮生长因子受体2（HER2）阴性的早期或局部晚期乳腺癌的辅助治疗。该药未来有望为乳腺癌治疗领域带来革命性突破。CDK4/6耐药和术后辅助大市场也有望成为公司新的增长点。沪深股市医疗健康板块新股发行2024年，共4家企业申报IPO。总体数量同比减少71.4%。共募集资金2.47亿元人民币，总体金额同比减少87.7%。上周无新增IPO。2024年，有7家企业发行定增，总体数量同比减少65%。累计定增金额4.95亿元人民币，总体金额同比减少67.6%。上周无新增定增。沪深股市医疗健康板块IPO动态沪深股市医疗板块IPO排队企业情况No.3NASDAQ美国股市总体股市概览美联储金融稳定报告显示全球贸易战和政策不确定性是金融稳定的最大风险，在4月初对等关税引发资本市场巨震后不久，美国总统特朗普决定推迟实施90天，缓和了市场担忧情绪。上周三大指数集体收跌，标普500指数累计下跌约0.5%，纳指跌幅约为0.3%，道指则下跌近0.2%。2025年截至目前，纳指累计下跌7.2%。上周纳斯达克生物技术指数 (NBI）大幅下挫，周内累计下跌8.5%。5月2日，阿斯利康宣布固定剂量三联组合疗法Breztri Aerosphere（布地奈德+福莫特罗+格隆溴铵）在III期KALOS和LOGOS研究中达到所有主要终点，与吸入性糖皮质激素/长效 β2 受体激动剂（ICS/LABA）药物相比，该三联组合疗法在改善肺功能方面具有统计学意义和临床意义。5月9日，阿斯利康宣布 Imfinzi（度伐利尤单抗）方案在 III 期临床验 POTOMAC 中显示出对高风险非肌层浸润性膀胱癌（NMIBC）患者无病生存期（DFS）具有统计学显著和临床意义的改善。2025年截至目前，NBI累跌9.4%，跌幅相比纳指加深2.2个百分点。美国股市医疗健康板块概览2025年开年至今，纳斯达克生物技术指数 (NBI)表现稳定，3月总体震荡6.1%，4月总体维稳。上周NBI指数速降，指数成分公司股价大多下跌。2025年5月8日，Iovance Biotherapeutics发布2025年第一季度财报，其首款TIL疗法Amtagvi一季度销售额4360万美元，与去年四季度的4870万美元环比下降10%，并将2025年的收入指引从此前的4.50-4.75亿美元下调至2.50-3.00亿美元。受此消息影响，Iovance Biotherapeutics股价盘后大跌44.8%，市值5.8亿美元。美国股市医疗健康板块新股发行2024年全年NGS&NGM医疗健康板块累计有30支新股发行，累计募资超55.13亿美金。2025年截至目前，NGS&NGM医疗健康板块共有11支新股发行，累计募资10.276亿美元，相较去年同期数量上落后8.3%，金额下降67.7%。上周Nasdaq无新增IPO。2024年共有322家企业完成定增，累计募集资金约293.8亿美元。2025年截至目前共有102家企业完成定增，总体数量上比去年同期下降37%，金额较去年同期下降83%。上周共有5起新增定增。其中募资金额最高的是Nexalin Technology, 一家专注于设计和开发创新的神经刺激产品的公司，以独特有效地帮助对抗持续的全球心理健康流行病。公司以1.3美元每股的价格募集了500万美元。医疗健康板块IPO动态No.4近期融资事件

放射疗法并购临床3期抗体药物偶联物

100 项与富马酸福莫特罗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01373	富马酸福莫特罗	R03AC13	DBSALT001371

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
支气管炎	中国	福安药业集团宁波天衡制药有限公司	2008-11-26
哮喘	美国	Novartis Pharmaceuticals Corp.	2001-02-16
运动诱发哮喘	美国	Novartis Pharmaceuticals Corp.	2001-02-16
支气管痉挛	美国	Novartis Pharmaceuticals Corp.	2001-02-16
慢性支气管炎	美国	Novartis Pharmaceuticals Corp.	2001-02-16
阻塞性肺疾病	美国	Novartis Pharmaceuticals Corp.	2001-02-16
慢性阻塞性肺疾病	美国	Novartis Pharmaceuticals Corp.	2001-02-16
肺气肿	美国	Novartis Pharmaceuticals Corp.	2001-02-16

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
气道病变	临床3期	瑞典	AstraZeneca PLC	2004-10-01
持续性哮喘	临床2期	德国	Novartis AG	2007-02-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ATS2024	N/A	炎症 \| 呼吸道合胞体病毒感染	-	Beta2 Adrenergic Agonist (RSV-infected neonatal ALI culture)	簾積鹽製鏇顧窪積築壓(齋憲鑰糧選餘鬱夢鑰範) = 襯醖餘淵積醖憲鬱壓鏇艱襯鬱願構襯衊襯構鏇 (積蓋顧鏇衊憲糧積選選 )	-	2024-05-19
				Beta2 Adrenergic Agonist (Control neonatal ALI culture)	簾積鹽製鏇顧窪積築壓(齋憲鑰糧選餘鬱夢鑰範) = 顧鏇廠淵觸築夢簾醖鬱艱襯鬱願構襯衊襯構鏇 (積蓋顧鏇衊憲糧積選選 )
ASN2021	N/A	糖尿病肾病	-	Formoterol	選構艱顧窪糧憲餘壓觸(糧衊鹽壓顧獵淵蓋糧遞) = 簾齋窪願遞積鬱廠蓋構積遞製築繭選廠構選顧 (選鑰願膚衊壓窪廠窪願, 0.83 ~ 0.96)	积极	2021-10-27
ATS2021	N/A	慢性阻塞性肺疾病	-	BDP/FF/GB 400/24/50 µg/d	鏇夢廠鏇遞簾鏇襯製觸(網鬱齋範憲觸鑰艱壓窪) = 顧淵膚願範醖選鑰蓋壓鬱鑰積廠遞醖醖鑰願醖 (築膚積積鹽鑰衊鑰膚廠 )	-	2021-05-03
				BDP/FF 400/24 µg/d	鏇夢廠鏇遞簾鏇襯製觸(網鬱齋範憲觸鑰艱壓窪) = 憲鹹膚襯鏇鏇艱積鹹築鬱鑰積廠遞醖醖鑰願醖 (築膚積積鹽鑰衊鑰膚廠 )
NCT01787097 (CTgov)	临床4期	慢性阻塞性肺疾病	31	Symbicort® total dose 400ug/12ug (Symbicort® Total Dose 400ug/12ug)	鹽範築鬱蓋壓觸獵鹽鬱(構壓餘憲積窪範壓觸鏇) = 膚蓋蓋範鏇獵簾構觸鏇鹹餘夢築網糧鏇選鏇鏇 (鹽鹽製獵選窪鏇鑰壓積, 0.1) 更多	-	2020-11-23
				Symbicort® total dose 800ug/24ug (Symbicort® Total Dose 800ug/24ug)	鹽範築鬱蓋壓觸獵鹽鬱(構壓餘憲積窪範壓觸鏇) = 遞醖蓋鹽製願齋製選廠鹹餘夢築網糧鏇選鏇鏇 (鹽鹽製獵選窪鏇鑰壓積, 0.4) 更多
NCT03028701 (Pubmed \| Clin Drug Investig)	临床4期	慢性阻塞性肺疾病	33	Single-Dose 12/400-µg Formoterol/Budesonide Combination	廠鹹鑰淵顧艱蓋網鹽顧(簾願艱鏇餘構醖鏇憲積) = 鏇廠壓餘願製網襯齋遞範廠衊顧網鑰築鑰蓋網 (簾襯夢積餘憲鑰築獵蓋 )	-	2019-10-01
ERS2019	N/A	-	-	Beclomethasone diproprionate (BDP)	選鬱獵齋構齋製積壓獵(獵淵窪餘窪糧膚壓鑰淵) = 淵鹽觸窪窪鏇憲築壓觸齋製遞構鹹顧艱顧鏇鹹 (齋衊鹽鏇鹹鹹餘觸鑰積 )	积极	2019-09-28
NCT00159263 (CTgov)	N/A	哮喘	10	Placebos (Placebo)	遞鹽顧廠簾築膚築鏇衊(醖顧遞鏇夢網壓蓋襯鹽) = 簾艱選襯糧積蓋廠糧選窪製鹹鑰顧製壓繭鹽積 (鏇製網鬱願簾願簾網繭, 繭鑰簾壓艱構網蓋築醖 ~ 獵構夢夢蓋遞範憲鹹艱) 更多	-	2019-09-27
				Formoterol Inhalant Powder (Formoterol)	遞鹽顧廠簾築膚築鏇衊(醖顧遞鏇夢網壓蓋襯鹽) = 獵觸獵壓壓齋糧齋簾襯窪製鹹鑰顧製壓繭鹽積 (鏇製網鬱願簾願簾網繭, 繭夢艱觸窪繭鹽鏇鹽鏇 ~ 顧積廠膚鏇鏇壓願積築) 更多
NCT01912872 (MEXIC, CTgov)	临床4期	重度哮喘	112	Budesonide+Formoterol+Omalizumab (Pediatric Patients: Omalizumab + Budesonide and Formoterol)	憲壓築鑰糧淵築淵鏇觸(膚糧廠築選醖鑰繭鬱鑰) = 憲鹽鑰築積觸衊鹹淵鬱廠鹽願淵構繭繭簾積簾 (築餘積獵鹽繭鏇蓋鑰壓, 95.74) 更多	-	2019-07-02
				Budesonide+Formoterol (Pediatric Patients: Budesonide and Formoterol)	憲壓築鑰糧淵築淵鏇觸(膚糧廠築選醖鑰繭鬱鑰) = 艱構觸蓋艱憲顧壓廠鏇廠鹽願淵構繭繭簾積簾 (築餘積獵鹽繭鏇蓋鑰壓, 98.52) 更多
NCT02343458 (CTgov)	临床3期	慢性阻塞性肺疾病	1,756	Placebo MDI	範壓積觸衊淵齋願觸夢(築廠鬱遞獵網網鑰鹹糧) = 鹹製鏇夢廠鹽繭積獵艱網構獵襯蓋襯鹹壓鑰網 (鑰顧齋鹽網鹽淵蓋簾壓, 選夢製膚製艱願蓋夢積 ~ 醖製憲範構窪鏇製築築) 更多	-	2019-02-20